Aethlon Medical Statistics
Total Valuation
Aethlon Medical has a market cap or net worth of $1.33 million. The enterprise value is -$3.18 million.
| Market Cap | 1.33M |
| Enterprise Value | -3.18M |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aethlon Medical has 2.37 million shares outstanding. The number of shares has increased by 331.78% in one year.
| Current Share Class | 2.37M |
| Shares Outstanding | 2.37M |
| Shares Change (YoY) | +331.78% |
| Shares Change (QoQ) | +53.18% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 7.50% |
| Float | 2.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.85 |
| Quick Ratio | 3.47 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -507.49 |
Financial Efficiency
Return on equity (ROE) is -142.89% and return on invested capital (ROIC) is -80.31%.
| Return on Equity (ROE) | -142.89% |
| Return on Assets (ROA) | -66.58% |
| Return on Invested Capital (ROIC) | -80.31% |
| Return on Capital Employed (ROCE) | -149.27% |
| Weighted Average Cost of Capital (WACC) | 9.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$794,608 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.77% in the last 52 weeks. The beta is 1.41, so Aethlon Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -95.77% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 2.66 |
| Relative Strength Index (RSI) | 22.65 |
| Average Volume (20 Days) | 132,329 |
Short Selling Information
The latest short interest is 228,466, so 9.64% of the outstanding shares have been sold short.
| Short Interest | 228,466 |
| Short Previous Month | 218,384 |
| Short % of Shares Out | 9.64% |
| Short % of Float | 9.72% |
| Short Ratio (days to cover) | 1.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.29M |
| Pretax Income | -7.15M |
| Net Income | -7.15M |
| EBITDA | -6.97M |
| EBIT | -7.29M |
| Earnings Per Share (EPS) | -$10.61 |
Balance Sheet
The company has $5.03 million in cash and $514,816 in debt, with a net cash position of $4.51 million or $1.90 per share.
| Cash & Cash Equivalents | 5.03M |
| Total Debt | 514,816 |
| Net Cash | 4.51M |
| Net Cash Per Share | $1.90 |
| Equity (Book Value) | 4.89M |
| Book Value Per Share | 3.11 |
| Working Capital | 4.12M |
Cash Flow
In the last 12 months, operating cash flow was -$7.00 million and capital expenditures -$3,704, giving a free cash flow of -$7.00 million.
| Operating Cash Flow | -7.00M |
| Capital Expenditures | -3,704 |
| Depreciation & Amortization | 323,653 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.00M |
| FCF Per Share | -$2.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Aethlon Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -331.78% |
| Shareholder Yield | -331.78% |
| Earnings Yield | -535.84% |
| FCF Yield | -524.65% |
Analyst Forecast
The average price target for Aethlon Medical is $3.25, which is 479.12% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.25 |
| Price Target Difference | 479.12% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 20, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Oct 20, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |